Publicly Traded RNAi Drug Firms | GenomeWeb

Publicly Traded RNAi Drug Firms


With Rosetta Genomics prepping for an initial public offering during this year or next, it is set to join a handful of other companies in the RNAi drugs game that are traded on public markets. To date Alnylam Pharmaceuticals is the only firm to have floated its shares as an RNAi company; all the others were already public when they reorganized to focus on the gene-silencing technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: diatom genetic diversity, microfluidic droplet method for single-cell screening, and more.

Scientific publishers are looking into whether artificial intelligence can help the peer-review process, Wired reports.

Researchers are using gene editing to develop more robust livestock and crops, AFP reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.